Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009
作者： Yan Xu , Hongyu Liu , Jun Chen , Qinghua Zhou
DOI: 10.1111/J.1759-7714.2010.00016.X
关键词: non-small cell lung cancer (NSCLC) 、 Medicine 、 Cancer treatment 、 Radiation therapy 、 Cancer 、 Lung cancer 、 Chinese version 、 Clinical Practice 、 Internal medicine 、 Oncology
摘要: The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for various malignant tumors have been widely recognized and followed by global oncologists, in order to promote the standardization of cancer treatment provide best recommendations patients. However, there are still some differences different countries areas based on specific conditions. In this paper, we compared between NCCN non-small-cell lung (Chinese version), original edition, European Society Medical Oncology guidelines.
blackwell-synergy.com参考文章(6)
Mark G. Kris, Ronald B. Natale, Roy S. Herbst, Thomas J. Lynch, Jr, Diane Prager, Chandra P. Belani, Joan H. Schiller, Karen Kelly, Harris Spiridonidis, Alan Sandler, Kathy S. Albain, David Cella, Michael K. Wolf, Steven D. Averbuch, Judith J. Ochs, Andrea C. Kay, Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial JAMA. ,vol. 290, pp. 2149- 2158 ,(2003) , 10.1001/JAMA.290.16.2149
Edward S Kim, Vera Hirsh, Tony Mok, Mark A Socinski, Radj Gervais, Yi-Long Wu, Long-Yun Li, Claire L Watkins, Mark V Sellers, Elizabeth S Lowe, Yan Sun, Mei-Lin Liao, Kell Østerlind, Martin Reck, Alison A Armour, Frances A Shepherd, Scott M Lippman, Jean-Yves Douillard, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial The Lancet. ,vol. 372, pp. 1809- 1818 ,(2008) , 10.1016/S0140-6736(08)61758-4
Frances A. Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano van Kooten, Mircea Dediu, Brian Findlay, Dongsheng Tu, Dianne Johnston, Andrea Bezjak, Gary Clark, Pedro Santabárbara, Lesley Seymour, Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 353, pp. 123- 132 ,(2005) , 10.1056/NEJMOA050753
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean-Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Horai, Kazumasa Noda, Ichiro Takata, Egbert Smit, Steven Averbuch, Angela Macleod, Andrea Feyereislova, Rui-Ping Dong, José Baselga, None, Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 21, pp. 2237- 2246 ,(2003) , 10.1200/JCO.2003.10.038
G D'addario, E Felip, None, Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Annals of Oncology. ,vol. 20, pp. 68- 70 ,(2008) , 10.1093/ANNONC/MDP132
Nick Thatcher, Alex Chang, Purvish Parikh, José Rodrigues Pereira, Tudor Ciuleanu, Joachim von Pawel, Sumitra Thongprasert, Eng Huat Tan, Kristine Pemberton, Venice Archer, Kevin Carroll, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) The Lancet. ,vol. 366, pp. 1527- 1537 ,(2005) , 10.1016/S0140-6736(05)67625-8